Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain
This article was originally published in The Tan Sheet
Executive Summary
At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.
You may also be interested in...
GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers
Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.